I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

SABCS 2024

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Dec 13 / Roche and Genentech
The global failure of mammography screening accessibility - a systematic literature review
Disparities in breast cancer (BC) outcomes between high-income and low-income countries result from social determinants and limited access to mammography screening, leading to later diagnoses and poorer prognoses. Understanding and addressing the barriers to BC care are critical for improving clinical outcomes and achieving the World Health Organization's 2021 Global Breast Cancer Initiative ambition (to reduce BC mortality by implementing early detection, timely diagnosis, and comprehensive BC management). This poster presents the findings from a systematic literature review of the barriers that women face in accessing mammography screening, diagnosis, and BC treatment. An estimation of the number of women worldwide affected by delays or lack of access to medical services is also reported.

Sign up or login to unlock the full suite of MEDICALLY features

Dec 12 / Roche and Genentech
ZN-1041, a potential best-in-class BBB Penetrable HER2 Inhibitor, has high antitumor activity in patients with Breast Cancer with CNS Metastases
This poster presents Phase Ic data evaluating the safety and efficacy of ZN-1041 in combination with trastuzumab and capecitabine, for the treatment of Chinese patients with HER2+ breast cancer brain metastases and extracranial disease.
11:30 PM
Duration 29mins San Antonio, USA
First-line inavolisib/placebo + palbociclib + fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months of adjuvant endocrine therapy completion: long-term safety from INAVO120
Saura C, Turner NC, Jhaveri K, Im SA, Loibl S, Schmid P, Loi S, Juric D, Tryfonopoulos D, Bedard P, Yap YS, Villanueva V, Gokmen E, Bondarenko I, Wang X, Papazisis K, Thanopoulou E, Shankar N, Lim S, Jin Y, Song C, Stout T, Kalinsky K

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 29mins San Antonio, USA
Real-world data on cyclin-dependent kinase 4/6 inhibitor switching in patients with first-line hormone receptor-positive, HER2-negative metastatic breast cancer
Chen L, Secrest M, Lopez-Valverde V, Perez-Moreno P, Kalinsky K, Zambelli A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:00 PM
Duration 30mins San Antonio, USA
ZN-1041, a potential best-in-class BBB Penetrable HER2 Inhibitor, has high antitumor activity in patients with Breast Cancer with CNS Metastases
Ma F, Li Y, Yao H, Wang J, Ouyang Q, Cheng J, Li X, Dinglin X-X, Jin G, Zhou H, Wang X, Teng Y, Wang Y, Dang Q, Yang J, Xiong H-H, Zhao W, Cai L, Fu T, Zhu D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:30 PM
Duration 29mins San Antonio, USA
pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen receptor-positive (ER+), HER2- locally advanced/metastatic BC (LA/mBC) with resistance to prior adjuvant endocrine therapy (ET)
Kalinsky K, Jeselsohn R, Bellet M, Fasching PA, Gomez-Abuin G, Jung KH, Lavalle S, Valverde VL, Lu YS, Schwab R, Turner NC, Breton VL, Zambelli A, Andre F

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 29mins San Antonio, USA
Preliminary safety analysis of the inavolisib + fulvestrant + ribociclib/abemaciclib arms in MORPHEUS-pan BC: a phase Ib/II study evaluating the efficacy and safety of multiple treatment combinations in patients with metastatic or locally advanced breast cancer
Sonnenblick A, Loi S, Martin H, Oliveira M, Soong J, Young F, Cahuzac C, Shemesh C, Song C, Kallapur K, Schwab R, Gal-Yam E

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 29mins San Antonio, USA
Real-world observational study of patients with endocrine-resistant, hormone receptor+, HER2– metastatic breast cancer in the first-line setting: Patient characteristics, PIK3CA mutation prevalence, treatments, and clinical outcomes
Dhillon P, Lambert P, Thanopoulou E, Kalinsky K

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:30 PM
Duration 29mins San Antonio, USA
DEMETHER: A single-arm phase II trial to evaluate the efficacy and safety of subcutaneous fixed-dose combination of pertuzumab and trastuzumab maintenance after induction treatment with trastuzumab deruxtecan (T-DXd) for previously untreated human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC)
Cortés J, Garcia Mosquera JJ, Antonarelli G, Gennari A, Barrios C, Curigliano G, Rugo H, Gligorov J, Harbeck N, Tolaney S, Gradishar WJ, Schmid P, Gion M, Zhan RR, Szostak E, Gonzalez-Alonso P, Verbeni M, Parez-Garcia JM, Llombart-Cussac A
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:30 PM
Duration 29mins San Antonio, USA
The global failure of mammography screening accessibility - a systematic literature review
Barrios C, Paluch-Shimon S, Muella E, Neeser K, Arnold M, Napalkov P, Azambuja E

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar